NCT03082144View on ClinicalTrials.gov

Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

May 30, 2018

Study Completion Date

December 30, 2018

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

MTX

MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total

DRUG

Ara-C

Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total

RADIATION

Radiotherapy

The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT03082144 - Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors | Biotech Hunter | Biotech Hunter